295 related articles for article (PubMed ID: 26040413)
21. Influence of Body Mass Index on the Prognostic Value of Tumor ¹⁸F-FDG Uptake in Stage I Non-Small Cell Lung Cancer.
Hyun SH; Lee KH; Choi JY; Kim BT; Kim J; Zo JI; Kim H; Kwon OJ; Ahn HK
PLoS One; 2015; 10(12):e0145020. PubMed ID: 26684001
[TBL] [Abstract][Full Text] [Related]
22. Relationship between pretreatment FDG uptake and local control after stereotactic body radiotherapy in stage I non-small-cell lung cancer: the preliminary results.
Hamamoto Y; Sugawara Y; Inoue T; Kataoka M; Ochi T; Takahashi T; Sakai S
Jpn J Clin Oncol; 2011 Apr; 41(4):543-7. PubMed ID: 21262874
[TBL] [Abstract][Full Text] [Related]
23. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
25. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non-small-cell lung cancer patients after stereotactic body radiotherapy.
Takeda A; Sanuki N; Fujii H; Yokosuka N; Nishimura S; Aoki Y; Oku Y; Ozawa Y; Kunieda E
J Thorac Oncol; 2014 Jan; 9(1):65-73. PubMed ID: 24346094
[TBL] [Abstract][Full Text] [Related]
26. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
Takahashi N; Yamamoto T; Matsushita H; Sugawara T; Kubozono M; Umezawa R; Ishikawa Y; Kozumi M; Katagiri Y; Tasaka S; Takeda K; Takeda K; Dobashi S; Jingu K
J Radiat Res; 2016 Nov; 57(6):655-661. PubMed ID: 27422935
[TBL] [Abstract][Full Text] [Related]
27. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
28. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
Dooms C; van Baardwijk A; Verbeken E; van Suylen RJ; Stroobants S; De Ruysscher D; Vansteenkiste J
J Thorac Oncol; 2009 Jul; 4(7):822-8. PubMed ID: 19487964
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of pre-treatment
Aktan M; Koc M; Kanyilmaz G; Yavuz BB
Ann Nucl Med; 2017 Jul; 31(6):462-468. PubMed ID: 28516335
[TBL] [Abstract][Full Text] [Related]
30. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
Tan D; Gill S; Loh N
Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
[TBL] [Abstract][Full Text] [Related]
31. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer.
Hoopes DJ; Tann M; Fletcher JW; Forquer JA; Lin PF; Lo SS; Timmerman RD; McGarry RC
Lung Cancer; 2007 May; 56(2):229-34. PubMed ID: 17353064
[TBL] [Abstract][Full Text] [Related]
32. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P
Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705
[TBL] [Abstract][Full Text] [Related]
33. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
34. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases.
Billè A; Okiror L; Skanjeti A; Errico L; Arena V; Penna D; Ardissone F; Pelosi E
Clin Lung Cancer; 2013 Mar; 14(2):149-56. PubMed ID: 22682667
[TBL] [Abstract][Full Text] [Related]
35. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
[TBL] [Abstract][Full Text] [Related]
36. The role of positron emission tomography following radiosurgical treatment of malignant lung lesions.
Gill BS; Rivandi AH; Sandhu SP; Jensen LG; Nobiensky PD; Hoh CK; Sandhu AP
Nucl Med Commun; 2012 Jun; 33(6):607-12. PubMed ID: 22546820
[TBL] [Abstract][Full Text] [Related]
37. FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
Kwon W; Howard BA; Herndon JE; Patz EF
J Thorac Oncol; 2015 Jun; 10(6):897-902. PubMed ID: 25811445
[TBL] [Abstract][Full Text] [Related]
38. Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.
Yamamoto T; Kadoya N; Shirata Y; Koto M; Sato K; Matsushita H; Sugawara T; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Ito K; Katagiri Y; Takeda K; Jingu K
Radiat Oncol; 2015 Feb; 10():35. PubMed ID: 25886315
[TBL] [Abstract][Full Text] [Related]
39. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
[TBL] [Abstract][Full Text] [Related]
40. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy.
Satoh Y; Nambu A; Onishi H; Sawada E; Tominaga L; Kuriyama K; Komiyama T; Marino K; Aoki S; Araya M; Saito R; Maehata Y; Oguri M; Araki T
Eur J Radiol; 2012 Nov; 81(11):3530-4. PubMed ID: 22178287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
